CTMX
CytomX Therapeutics, Inc.NASDAQHealthcare$4.56+0.00%ClosedMarket Cap: $776.3M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
7.56
P/S
9.83
EV/EBITDA
-38.20
DCF Value
$-4.19
FCF Yield
-10.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
99.3%
Operating Margin
-29.3%
Net Margin
-22.8%
ROE
-19.8%
ROA
-11.4%
ROIC
-20.3%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $663.0K | 23.1% | $-27.9M | $-26.5M | $-0.17 | — |
| FY 2025 | $76.2M | 100.0% | $-19.6M | $-17.4M | $-0.15 | — |
| Q3 2025 | $6.0M | 100.0% | $-15.8M | $-14.2M | $-0.09 | — |
| Q2 2025 | $18.7M | 100.0% | $-1.3M | $-154.0K | $-0.00 | — |
| Q1 2025 | $50.9M | 100.0% | $22.6M | $23.5M | $0.27 | — |
| Q4 2024 | $38.1M | 100.0% | $17.7M | $18.9M | $0.24 | — |
| FY 2024 | $138.1M | 100.0% | $25.0M | $31.9M | $0.38 | — |
| Q3 2024 | $33.4M | 100.0% | $4.1M | $5.7M | $0.07 | — |
| Q2 2024 | $25.1M | 100.0% | $-8.5M | $-6.5M | $-0.08 | — |
| Q1 2024 | $41.5M | 100.0% | $11.7M | $13.8M | $0.17 | — |
| Q4 2023 | $26.6M | 100.0% | $-606.0K | $837.0K | $0.01 | — |
| FY 2023 | $101.2M | 100.0% | $-6.5M | $-569.0K | $-0.01 | — |